[{"id":"69e83241-ea93-4a7c-a2c5-2fc40b9cacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03964233","created_at":"2021-01-18T19:30:14.916Z","updated_at":"2024-07-02T16:34:27.457Z","phase":"Phase 1","brief_title":"A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)","source_id_and_acronym":"NCT03964233","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53 • MDM2","pipe":" | ","alterations":" TP53 mutation • TP53 wild-type • TP53 amplification","tags":["TP53 • MDM2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • TP53 wild-type • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 06/11/2019","start_date":" 06/11/2019","primary_txt":" Primary completion: 09/03/2024","primary_completion_date":" 09/03/2024","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-06-11"},{"id":"e836e839-556f-4146-93d2-b74e4f803dd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03433898","created_at":"2021-01-18T16:56:19.022Z","updated_at":"2024-07-02T16:35:41.637Z","phase":"Phase 1","brief_title":"This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer","source_id_and_acronym":"NCT03433898","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 02/23/2018","start_date":" 02/23/2018","primary_txt":" Primary completion: 07/20/2023","primary_completion_date":" 07/20/2023","study_txt":" Completion: 07/20/2023","study_completion_date":" 07/20/2023","last_update_posted":"2023-07-28"},{"id":"c202d09f-4287-4463-8629-079b1034deac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03156114","created_at":"2021-01-18T15:33:42.030Z","updated_at":"2024-07-02T16:35:44.324Z","phase":"Phase 1","brief_title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","source_id_and_acronym":"NCT03156114","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 03/09/2023","primary_completion_date":" 03/09/2023","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-06-29"}]